BACKGROUND: Bladder cancer represents the fifth most common malignancy worldwide and a major cause of cancer-related morbidity and death. Incidence and mortality rates have remained relatively constant over the past four decades. Urothelial bladder cancers have identified multiple risk factors.
Introduction
In Egypt, bladder cancer accounts for about 30% of all cancers, with many pathogenic factors most commonly schistosomal infestation, which is an endemic disease in Nile River area [1] . In areas where schistosomiasis is endemic there is a high incidence of squamous cell carcinoma of the urinary bladder. Schistosomiasis causes chronic granulomatous cystitis leading to squamous metaplasia of transitional epithelium, and subsequently development of squamous cell carcinoma [2] . Transitional cell carcinoma is the most common type of bladder cancer. It arises primarily from transitional cells of bladder mucosal epithelium and may be present as non-invasive papillary or non-papillary tumours [3] .
The interaction between transitional cell carcinoma cells and the adjacent or underlying bladder stroma may be an important determinant in the progression of superficial to invasive disease [4] . Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLCγ1, PI3K, and STATs [5] . Fibroblast growth factor receptor three signalling is altered in a high proportion of bladder tumours. Activating mutations and overexpression of FGFR3 are common in urothelial tumours with low malignant potential and low-stage and -grade urothelial carcinomas and are associated with a lower risk of progression and better survival in some subgroups [5] . FGFR3 mutations are linked to favourable (low grade/stage) pTa bladder cancer [6] . Fibroblast Growth Factor receptor 3 (FGFR3) mutations are most common in low-risk NMIBC (non-muscle invasive bladder cancer), a subset of MIBC (muscle invasive bladder cancer) that carries FGFR3 mutations shows particularly poor prognosis [7] . Foth et al., [7] stated that FGFR3 activation leads to urothelial cell abnormalities in the absence of Pten gene. The fgfr3 expression is present in both primary and metastatic urothelial cancer, and the majority of metastases retain immmunohistochemical expression of FGFR3 if it was expressed in the primary tumour [8] . Subsequent larger studies established that FGFR3 mutations occur in around 50% of both lower and upper urinary tract tumours and these cluster in three distinct hotspots in exons 7, 10, and 15 [6, 9] . FGFR3 mutations are thought to induce a conformational change in the kinase domain resulting in ligand-independent receptor activation and signalling; they have also been shown to alter FGFR3 cellular localisation, inducing aberrant signalling from the endoplasmic reticulum [10] .
FGFR3 mutation status was the strongest predictor of recurrence when compared with stage and grade. This is the first mutation in bladder cancer that selectively identifies patients with favourable disease characteristics [11] .While FGFR3 mutation or copy number gain is a rare event, studies of these tumours may shed light on how FGFR3 signalling contributes to urothelial carcinoma growth and proliferation [8] . Furthermore, based on preclinical studies that suggest the FGFR pathway, and specifically FGFR3, may be a valid therapeutic target, we believe this area of investigation warrants further exploration [8] . In vitro and in vivo studies have shown that FGFR inhibition has cytotoxic and cytostatic effects in FGFR-dependent bladder cancer cells and FGFR-targeted agents are currently being investigated in clinical studies for the treatment of urothelial carcinoma [5] . Overall, FGFRs hold promise as therapeutic targets, diagnostic and prognostic markers, and screening tools for early detection and clinical management of urothelial carcinoma [5] .
In our study, we are aiming to evaluate the association of FGFR3 expression and gene mutation and its risk in the development of urothelial carcinoma (bilharzial and non-bilharzial), the effect on grading and staging of the tumour and the benefit of using this marker as a therapeutic target and diagnostic tool in bladder cancer patients.
Patients and Methods
The material of this study included 110 formalin fixed paraffin embedded (FFPE) biopsies.
The cases were included according to the following criteria:
Inclusion criteria: Adult Cases with bladder cancer; with different grades and stages; with or without bilharzial cystitis; nature of the specimen: TUR-T or radical cystectomy;
Exclusion criteria: receiving chemotherapy and radiotherapy; children.
Groups
According to [12] [13] , the 110 cases were categorised into the following groups:
Group (1): Control; 5 cases. These cases were (4 males and 1 female with age range 20-46 y) with normal, healthy urothelium, and served as controls undergoing cystoscopy for other reasons than lower urinary tract symptoms, such as ureteroscopy or ureteric catheter or double J-insertion and biopsies were taken upon their consent.
Group (2):
Cystitis: a) Bilharzial cystitis, 9 cases; b) Non-Bilharzial cystitis, 6 cases. 
Immunohistochemical procedure
Immunohistochemistry for FGFR3 was performed on sections cut from the paraffin blocks with a commercially available rabbit monoclonal Anti-FGFR3 antibody (sc-13121, Santa Cruz, USA). Slides were sectioned at 4μm onto positively charged slides (Superfrost Plus, Menzel-Glaser, Germany) and the slides were stained on an automated platform the (Dako Autostainer Link 48). Heat-induced antigen retrieval was used for 30 min at 97°C in the high-PH EnVision™ FLEX Target Retrieval Solution, and the primary antibody was used at a dilution of 1 in 100. The detailed histopathological assessment was done regarding confirmation of diagnosis and grading of malignant cases.
Immunohistochemical assessment was done according to [9] . Cells with membrane cytoplasmic staining were considered positive: The intensity and extent of cells stained positively for FGFR3 was evaluated by assessing 10 high-power microscopic fields by two independent pathologists (OH &TA): *Score 0: All tumor cells are negative; *Score +1: Weak but detectable positivity in some or all cells; *Score +2: moderate but extensive positivity; and *Score +3: strong positivity (regardless of extent).
Fluorescence in situ hybridization (FISH) technique
The probe contains green-labeled polynucleotides (Zygreen) which target FGFR3 gene and orange-labeled polynucleotides which target sequences of chromosome 4 in the chromosomal region 4p11. The code number of the used probe is (ZytoLight ® SPEC FGFR3/4p11 Dual Color Probe, Previously: ZytoLight SPEC FGFR3/CEN 4 Dual Color Probe).
Sections were de-waxed, then incubated for 10 minutes at 70% on a hot plate, followed by incubation for 2x 10 minutes in xylene then rehydrated in 100%, 100%, 90%, and 70% ethanol, each for 5 minutes and lastly washed 2x2 minutes in distilled water. Sections were incubated for 15 minutes in prewarmed Heat Pretreatment Solution Citric at 98, then transferred immediately to distilled water, washed for 2x2 minutes and water was drained off. Pepsin solution was applied to tissue sections that were incubated for 10 minutes at 37 in a humidity chamber. After that, sections were washed for 5 minutes in Wash Buffer SSC and 1 minute in distilled water. The following steps were then successively done: Dehydration in 70%, 90%, and 100% ethanol, each for 1 minute. Air dry sections then, pipette 10μl Zytolight FISH probe each onto individual samples. Cover the samples with a coverslip (with hot glue from an adhesive pistol). Denature the slides at 75 ºC for 10 minutes on a hot plate. Transfer the sections to a humidity chamber and hybridise overnight at 37ºC. Remove the glue carefully and remove the coverslip by submerging in 1x Wash Buffer for 2x5 minutes at 37 ºC for 1-3 minutes. Incubate the slides in 70%.90%, and 100% each for one minute.
Air dry samples protected from light. Cell nuclei were stained by pipetting 30μl DAP/Dura-Tectsolution onto the sections. Avoiding trapped bubbles cover the samples with a coverslip. Carefully remove excess DAP/Dura-1-solution by gently pressing the slide between filter papers. Store the slides in the dark. For longer storage periods; this should take place at 2-8C. Evaluation of the sample material; is carried out by Fluorescence microscopy.
Interpretation of FISH
Evaluation of the FGFR3 gene is carried out by fluorescence microscopy (Olympus X51) [using three filters red (FITC), green, and DAPI] using a × 1000 oil immersion objective lens. The microscope is attached to a high-resolution video camera (Jale) and monitor. We captured and interpreted photos using hardware (Cytovision 2.3, USA). SPEC FGFR3 Dual Color Probe hybridized to normal interphase as indicated by two orange/green fusion signals per nucleus no amplification of Fibroblast growth factor receptor 3 (FGFR3), SPEC FGFR3 Dual Color Probe hybridized with interphase cells showing an over expression of chromosome 4 as indicated by multiple green more than orange signals in the nuclei according to [14] .
Statistical analysis
SPSS software version 18 was used for data management and analysis. Quantitative data were presented as mean ± SD. Qualitative data were presented as frequencies and percentages. To study the relationship between variables, Spearman's correlation coefficient was calculated. Tests were considered statistically significant when P< 0.05.
Results

Sex distribution in different lesions studied
Urothelial lesions were more predominated in males; as 12 out of 15 cases (80%) with chronic cystitis, 11 out of 15 cases with squamous cell carcinoma (73%) and 49 out of 75 cases with transitional cell carcinoma (65%) were males. The highest frequency of urothelial carcinomas was in the seventh decade (51.2%) ( Table 1) . In the malignant group; 61 out of 90 cases (67.8%) were positive for FGFR3 immunostaining; thirty-three cases were of mild intensity, 19 cases were of moderate intensity, and 9 cases were of marked intensity. There was a significant difference between malignant group and control group at p-value <0.01 (Table 2; Fig. 1: A-D) .
Seventy-two percent of TCC cases were positive for FGFR3 by immunostaining with mild, moderate, and marked staining (38.6%, 21.4% and 12%) respectively. Seven cases out of 15 squamous cell carcinoma cases (46.7%) were positive for FGFR3 expression with mild and moderate immunostaining in 26.7% and 20% respectively (Table  3 ). There was a significant inverse correlation between the score of expression and both the stage and the grade of malignancy (p<0.05 and p<0.01 respectively) ( Table 4 ; Fig. 1 A total of 88.2% of TCC cases showed FGFR3 gene amplification; mostly were of low grade (70%) and showed a significant difference at p-value < 0.01 compared to high grade. In NMIBC group (80%) there is a statistical difference of FGFR3 gene amplification at p-value 0.01 compared to MIBC group. While all cases of SCC have FGFR3 gene amplification, most of the positive cases were of high grade and belong to the MIBC group (83.3%) with a significant difference at p-value < 0.01 compared to high grade and NMIBC group. Almost all cases of SCC and TCC associated with bilharziasis report FGFR3 gene amplification with a significant difference between TCC on bilharzial compared to TCC bilharzial groups at P value < 0.05 (Table 5 ). Amplified FGFR3 gene was documented in 90% of malignant cases with mild FGFR3 staining intensity and 84.6% of positive malignant cases with moderate staining intensity showing a significant difference compared to the negative malignant cases with moderate intensity at p-value < 0.01.
: E-H).
Figure 1: (A) Case of bilharzial cystitis with proliferative changes( Brunn`s nests) and calcified bilharzial ova (H&E, X 100); (B) Case of Papillary urothelial carcinoma low grade , not invading lamina (Ta) (H&Ex50); (C) Case of urothelial carcinoma high grade, invading lamina and muscle layer (T2) associated with bilharziasis (H&E x200); (D) Case of Squamous cell carcinoma with calcified bilharzial ova, high grade, invading lamina and muscle layer (T2) (H&E x200); (E) Case of cystitis, negative for FGFR3 immunostaining (IHC, DAB, x100); (F) Case of papillary urothelial carcinoma low grade, not infiltrating lamina Ta, strongly positive for FGFR3 immunostaining. (IHC, DAB, x100); (G) Case of a case of urothelial carcinoma high grade, infiltrating lamina and muscle layer T2, positive cytoplasmic for FGFR3 immunostaining, mild intensity (IHC, DAB, x200); (H) Case of squamous cell carcinoma highgrade, malignant cells show positive cytoplasmic for FGFR3 immunostaining, mild intensity. (IHC, DAB, x200)
FGFR3 expression by FISH
Figure 2: (A) SPEC FGFR3 Dual Color Probe hybridized to normal interphase as indicated by two orange/green fusion signals per nucleus from a case of TCC Ta GI showing malignant cells with normal expression, no amplification of Fibroblast growth factor receptor 3 (FGFR3) as two FGFR3 signals (green) and two chromosome 4 signal (orange/red) (red arrows) (FISH, magnification ×1000); (B) Urinary bladder tissue from a case of SCC, SPEC FGFR3 Dual Color Probe hybridized with interphase cells showing polysomy of chromosome 4 as indicated by multiple green and orange signals in the nuclei (magnification ×1000); (C)
Amplified FGFR3 gene was reported in 85.7% of low-grade tumours with marked staining intensity showing a significant difference compared to the highgrade tumours at p-value < 0.01. Amplified FGFR3 gene was also reported in 92.3% in NMIBC with moderate staining intensity showing a significant difference compared to MIBC group at P value < 0.01 (Table 6 ; Fig. 2 : A-D). 
Discussion
Schistosomiasis is not known to be associated with any malignant disease other than bladder cancer. In Egypt, the frequency rate of the bladder cancer has declined significantly during the last 25 years. This drop is mainly related to the control of schistosomiasis [15] . In the present work, the incidence of bilharzial infestation in malignant studied cases was about 40%, and this was close to what was mentioned by Abdulamir et al. [16] . Also, all cases of SCC were associated with bilharzial affection and this in agreement with [17] who stated that Schistosoma infection-induced urinary bladder carcinogenesis and also in agreement with Khaled et al. [15] who stated that bladder cancer associated with schistosomal infection has a high occurrence of SCC type. We found that FGFR3 expression was negative in control group and this finding is compatible Gust et al. [18] . There was no evidence of such staining in normal urothelium. We also found that 72 % of malignant cases were positive for FGFR3 immunostaining, which is compatible with Junker et al. [19] who stated that expression of FGFR3 was found in approximately 70% of both low and highgrade tumours, as well as equally distributed between invasive and non-invasive urothelial carcinoma.
In our study, 88% of urothelial carcinoma cases positive for FGFR3 immunostaining were superficial non-invasive tumours. A recent study done on 255 primary urothelial carcinomas reported that 63.5 % of superficial carcinoma were positive for FGFR3 protein expression by immunophenotyping, while only 33% of invasive muscle tumours were positive [20] .
About 92 % of low-grade urothelial cancers of our cases were positive for FGFR3 immunostaining, and this is compatible with Poyet at al. [20] who found that 69.4% of low-grade urothelial carcinoma were positive to FGFR3, while only 26.7% of high-grade tumours were positive for FGFR3. We also reported that all cases of SCC were of high grade and with muscle invasion and this was in agreement with Abdulamir et al. [16] and Salim et al. [17] . About half of the SCC cases in the present study were positive for FGFR3 immunostaining, and this was also explained by Salim et al. [17] who stated that SCC showed a predisposition to a high level of FGFR3 protein expression and mutation. The fish technique was applied to forty malignant cases with FGFR3 protein overexpression to detect gene amplification of FGFR3. We found that 36 cases out of 40 cases of malignancy (90%) were positive, which is close to Tomlinson et al. [9] who mentioned that an association between expression level and mutation status. Fifty-five percent of positive cases were of low grade, and 77.7% were in NMIBC group. This result is close to what was reported by Junker et al. [19] who stated that 63% of NMBIC group and 59% were at low-grade show FGFR3 gene amplification.
We found positivity for FGFR3gene amplification in almost all bilharziasis associated malignant cases (SCC and TCC). All cases of bilharziasis associated SCC cases showed FGFR3 gene amplification. They were mostly of high grade and were in MIBC group. This was previously mentioned by Khaled et al. [15] who explained that by chromosomal alterations that characterise schistosomal bladder cancer cases. FGFR3 point mutations, overexpression of FGFR3 protein has been described. Although this overexpression was associated strongly with the presence of FGFR3 mutations (up to 85% of FGFR3-mutated tumours show strong FGFR3 protein expression), FGFR3 overexpression was also found in 40% of tumours with wild-type FGFR3, particularly in those with an invasive phenotype [9, 21] .
We detected FGFR3 gene amplification in 88.2% of the TCC cases; about 70% were of low grade, and 80% were in NMIBC group. Amplified FGFR3 gene was documented in 90% of malignant cases with mild FGFR3 staining intensity; in 84.6% with moderate staining intensity and in all cases with marked staining intensity. Similar results were also achieved by Tomilinson et al. [9] who stated that there http://www.mjms.mk/ http://www.id-press.eu/mjms/ is an association between expression level and mutation status also Fischbach et al. [22] found in their study all FGFR3amplified samples showed concomitant FGFR3 mutations and FGFR3 protein overexpression.
In conclusion, our findings suggest that invasive tumours may develop either from carcinoma in situ or Ta cases having multiple genetic alterations together including gene amplifications in bilharzial associated carcinomas. Estimation of FGFR3 expression could serve as a prognostic indicator in the follow-up of cancer bladder patients along surgical or therapy managements, especially in bilharzial associated malignant cases. Expression of FGFR3 could also be utilised for molecular targeted therapy in urinary bladder cancer, so, we need further studies to target these molecular markers to outline an effective treatment strategy for the bladder cancer shortly.
